ALGS - Aligos Therapeutics Inc
6.98
0.320 4.585%
Share volume: 87,271
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.17%
PREVIOUS CLOSE
CHG
CHG%
$6.66
0.32
0.05%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-06-2024 | 11-06-2024 | 03-10-2025 | 05-06-2025 | 11-06-2025 | 03-05-2026 | |
| Assets | ||||||||
| Total Assets | 127.902 M | 108.811 M | 88.426 M | 70.094 M | 150.699 M | 109.764 M | 88.533 M | |
| Current Assets | 118.064 M | 99.570 M | 79.822 M | 62.141 M | 143.205 M | 103.435 M | 82.862 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 5.109 M | 4.964 M | 4.790 M | 5.092 M | 5.234 M | 4.229 M | 4.908 M | |
| Short Term Investments | 88.588 M | 49.458 M | 39.591 M | 19.942 M | 64.098 M | 57.150 M | 59.541 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 24.151 M | 45.078 M | 35.331 M | 36.997 M | 73.763 M | 41.946 M | 18.303 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 3.046 M | 2.797 M | 2.575 M | 2.362 M | 2.214 M | 2.035 M | 1.867 M | |
| Other Assets | 6.792 M | 6.444 M | 6.029 M | 5.591 M | 5.280 M | 4.294 M | 3.804 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 127.902 M | 108.811 M | 88.426 M | 70.094 M | 150.699 M | 109.764 M | 88.533 M | |
| Total liabilities | 68.106 M | 41.582 M | 38.330 M | 99.067 M | 34.254 M | 37.931 M | 34.988 M | |
| Total current liabilities | 18.880 M | 23.564 M | 20.956 M | 21.737 M | 18.948 M | 21.987 M | 21.233 M | |
| Accounts Payable | 2.842 M | 6.819 M | 2.740 M | 2.571 M | 4.460 M | 4.651 M | 3.982 M | |
| Other liabilities | 49.009 M | 18.018 M | 17.186 M | 77.330 M | 15.184 M | 15.822 M | 13.755 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 49.009 M | 18.018 M | 17.186 M | 77.330 M | 15.184 M | 15.822 M | 13.755 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 59.796 M | 67.229 M | 50.096 M | -28.973 M | 116.445 M | 71.833 M | 53.545 M | |
| Common stock | 580.980 M | 583.334 M | 585.377 M | 588.584 M | 690.918 M | 693.698 M | 695.278 M | |
| Retained earnings | -521.660 M | -516.599 M | -535.858 M | -618.008 M | -574.920 M | -622.320 M | -642.201 M |